Cambridge-based Alchemab Therapeutics has secured a significant £25 million investment from the British Business Bank, extending its Series A financing. This new capital brings the company's total Series A funding to £109 million. The funds are earmarked for advancing its clinical pipeline and dramatically expanding its proprietary antibody dataset to over one billion sequences.
A Novel Approach to Drug Discovery
Alchemab pioneers a unique method for discovering new medicines by studying individuals who show unusual resilience to hard-to-treat diseases. The company's Resiliome™ platform integrates deep B cell sequencing, computational analysis, and advanced AI algorithms. This technology allows researchers to identify naturally occurring protective antibodies that help these individuals resist or overcome illness.
The process begins by identifying these resilient individuals and analyzing their antibody repertoires to find convergent protective responses. By sequencing millions of antibody sequences, Alchemab's platform can pinpoint the specific antibodies responsible for this protection. These antibodies are then developed into first-in-class therapeutic candidates for patients lacking this natural defense mechanism.
Strategic Expansion and Pipeline Advancement
The latest funding will be instrumental in scaling Alchemab's core asset, its extensive antibody database. The company plans to double its dataset from 500 million to over a billion antibody sequences. This expansion will significantly enhance the power of its AI-driven drug discovery engine, increasing the potential for new breakthroughs.
Beyond data expansion, the investment will accelerate the development of additional therapeutic candidates into clinical trials. This move builds upon the momentum from the company's initial successes and investor confidence. The goal is to translate promising research into a robust pipeline of novel treatments for various unmet medical needs.
Validating the Platform with ATLX-1282
Alchemab's platform has already demonstrated significant potential through its first asset, ATLX-1282. This first-in-class antibody therapeutic is currently in clinical development for amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease. The progress of ATLX-1282 serves as a powerful validation of the company's innovative discovery approach.
In a major milestone, Alchemab entered into a licensing agreement with Eli Lilly and Company for ATLX-1282. The deal, worth up to $415 million, includes an upfront payment and future royalties, with Lilly leading later-stage development. This partnership underscores the commercial viability and scientific promise of therapies derived from the Resiliome™ platform.
Investor Confidence and UK Biotech Growth
The investment, the largest to date by the British Business Bank in a life sciences company, signals strong confidence in Alchemab's long-term potential. CEO Dr. Jane Osbourn stated the funding validates their platform and will accelerate the development of therapeutics for conditions with significant unmet need. Dame Kate Bingham, Chair of Alchemab, highlighted the investment's role in scaling innovative UK biotech companies globally.
Representatives from the British Business Bank praised Alchemab's position at the cutting edge of UK scientific capability. Dr. Carmine Circelli noted the company's powerful combination of a large proprietary dataset with advanced AI to unlock new treatments. The investment reflects a commitment to providing long-term capital to help the UK's most innovative biotech firms succeed.
This £25 million capital injection marks a pivotal moment for Alchemab Therapeutics, reinforcing its position as a leader in AI-driven drug discovery. By expanding its unique antibody database and advancing its clinical pipeline, the company is well-positioned to deliver transformative treatments. The continued support from investors like the British Business Bank highlights the immense potential of harnessing the body's natural resilience to combat disease.